Regardless of cancer type, ICI-related CRS safety reports were more numerous on anti-PD-1/PD-L1 antibodies, in line with the single case reports of CRS developed on either nivolumab or pembrolizumab (Foran et al., 2017; Rassy et al., 2017; Rotz et al., 2017; Zhao et al., 2018; Dimitriou et al., 2019; Honjo et al., 2019; Kogure et al., 2019; Oda et al., 2019). This evidence concerns the gene CD274 and congenital rubella syndrome.